Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – Time to Sell?

Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Tuesday . The stock traded as low as $74.07 and last traded at $74.20, with a volume of 21131580 shares trading hands. The stock had previously closed at $76.27.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Morgan Stanley reduced their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. lowered their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. UBS Group reduced their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Price Performance

The company has a market cap of $110.00 billion, a price-to-earnings ratio of 38.25, a PEG ratio of 1.60 and a beta of 0.67. The company has a 50-day simple moving average of $92.85 and a 200-day simple moving average of $98.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of institutional investors have recently bought and sold shares of the company. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Finally, United Community Bank raised its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.